Navigation Links
Lilly Completes Cash Tender Offer for ImClone Systems
Date:11/21/2008

rm Act of 1995 and the Federal securities laws. Although ImClone believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions it can give no assurance that its expectations will be achieved. Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those currently expected. Many of these factors are beyond ImClone's ability to control or predict. For forward-looking statements in this news release, other than those statements that relate to the tender offer, ImClone claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. WWMR Announces Pain Clinic Physicians Most Appreciated Companies: Pfizer, Eli Lilly and Endo Pharmaceuticals
2. Lilly Contributes $11.1 Million to United Way Annual Campaign
3. Lilly Announces Launch of Color Differentiation System for Humalog(R) and Humulin(R) U-100 Insulin Products in the United States
4. Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly
5. Lilly to Take Charge to Earnings Related to Pending Federal and State Investigations of Past Practices
6. Lilly Declares Fourth-Quarter Dividend
7. Douglas Oberhelman Elected to Lilly Board of Directors
8. Lilly Commences Cash Tender Offer for ImClone Systems at $70 Per Share
9. Lilly Recognized as One of the Worlds Top Biopharmaceutical Employers
10. Update: The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline
11. The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015  Pfenex Inc. (NYSE ... the development of biosimilar therapeutics, today announced that ... Global Healthcare Conference in Miami, FL at the Loews Miami ... executive officer of Pfenex, will provide an overview ... on March 12th at 9:00 am ET. A live audio webcast ...
(Date:3/2/2015)... YORK , March 2, 2015 ... scroll to bottom.   Moments ago, Analysts ... including Sunshine Heart (NASDAQ: SSH ), ... ), Syneron Medical (NASDAQ: ELOS ), Spectranetics (NASDAQ: ... ). Analysts Review provides a single unified platform for investors, ...
(Date:3/2/2015)... , March 2, 2015 VG ... developing therapies for autoimmune and infectious diseases, announced ... has issued an important new composition of matter ... through the targeting of CLIP. ... technology underlying VG Life Sciences, VG1177, a synthetic ...
(Date:3/2/2015)... March 02, 2015 Global ... formed alliance with Shenzhen HANK Bioengineering Co., Ltd. ... The alliance will establish a stem cells training ... China in September 2015. , Shenzhen HANK is ... an award-winning scientist, microbiologist and virologist, to integrate ...
Breaking Biology Technology:Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 2Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 3Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 4VG Life Sciences Granted Key Composition Of Matter Patent 2VG Life Sciences Granted Key Composition Of Matter Patent 3Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 3
... Avastin(R) May Slow Tumor Growth, ROCKVILLE, ... ENMD ), a clinical-stage pharmaceutical company developing,therapeutics ... diseases, today,announced the presentation of interim results ... NCD with Avastin(R) (bevacizumab) in patients,with advanced ...
... Sanofi-aventis announced,today that the anticoagulant Clexane(R) (enoxaparin ... Japan by the Ministry of Health, Labour ... (VTE) in patients,undergoing orthopaedic surgery of the ... knee replacement and hip fracture surgery., ...
... Forest Laboratories, Inc.,(NYSE: FRX ), Forest Laboratories ... Merz Pharmaceuticals GmbH announced that they have filed ... the District of Delaware against,additional companies for infringement ... relates to Forest,s Namenda(R) product. The defendants,named in ...
Cached Biology Technology:EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study 2EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study 3EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study 4Clexane(R)/Lovenox(R) Approved in Japan 2Clexane(R)/Lovenox(R) Approved in Japan 3Clexane(R)/Lovenox(R) Approved in Japan 4Clexane(R)/Lovenox(R) Approved in Japan 5Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KgaA File Additional Lawsuit Against Several Companies for Patent Infringement 2
(Date:2/18/2015)... , Feb. 18, 2015  Cepheid (NASDAQ: ... at the following conferences, and invited investors to participate via ... Boston, MA Tuesday, March 3, 2015 at ... Conference, Orlando, FL Wednesday, March 4, ... Webcasts To access the live webcasts for these events, please ...
(Date:2/11/2015)... February 11, 2015 ... "Access Control Market by Product (Cards and Readers, Biometrics, ... Defense, Government, Industrial, Healthcare, Education) and By Geography - Global ... MarketsandMarkets, the Access Control Market is expected ... at a CAGR of 10.6% between 2014 ...
(Date:2/5/2015)... 2015  Marken is starting its 35 th ... a new marketing campaign to solidify its place as ... campaign focuses on First as a primary ... The first headline in the series, ... its client,s priorities. Marken recognizes the need to protect ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2
... The ongoing dance between a virus and ... human adenoviruses typically cause mild infections, recent reports have ... fatal, human infections. Researchers from the Massachusetts ... for Public Health, School of Systems Biology, George Mason ...
... balls that can zap pain and lung tumors to ... physicians will present the latest research on cutting-edge treatments ... Meeting April 13󈝾 at the Ernest N. Morial Convention ... the theme "IR Reaching Out" and delivers education, resources ...
... have identified a new potential therapeutic target for lowering ... to statins. Scientists in the lab of ... action of a gene responsible for transporting a protein ... remove cholesterol from the blood in mice. Trapping the ...
Cached Biology News:Society of Interventional Radiology: 38th Annual Scientific Meeting 2U-M researchers find new way to clear cholesterol from the blood 2
Silica bead method is an economic method of DNA extraction from agarose...
DTT, 25g...
... are commonly used in baculovirus ... grade" agaroses either contain contaminants ... cells or lack the physical ... overlays. Novagen's BacPlaque Agarose is ...
Antibody specific for trimethyl-Lys27 of histone H3. Mouse monoclonal. Antigen: Synthetic peptide derived from histone H3, trimethylated at lysine 27...
Biology Products: